SGMOQ on OTC

SANGAMO THERAPEUTICS, INC

We are a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Kymera Therapeutics, Voyager Therapeutics (United States) or Editas Medicine, or pick any stock.

  • TickerSGMOQ on OTC1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersRichmond, California1
  • Incorporated inDE2
  • Business address501 Canal Blvd., Richmond, Ca 940842
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. We believe our zinc finger epigenetic regulators are ideally suited to potentially address devastating neurology disorders and our capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system, or CNS, in preclinical studies.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-306.5%Operating margin4
-310.8%Net margin4
-31.6%Revenue growth, 20254
-$97.3MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development99¢$112.7M
  • Income tax1¢$568.0K

Out of $39.6M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$39.6M in 2025−61% since 2019
0$50.0M$100.0M$150.0M$200.0M2019: $102.4M$102.4M20192020: $118.2M$118.2M2020+15%2021: $110.7M$110.7M2021−6%2022: $111.3M$111.3M2022+1%2023: $176.2M$176.2M2023+58%2024: $57.8M$57.8M2024−67%2025: $39.6M$39.6M2025−32%
Operating income56784-$121.2M in 2025+15% since 2019
-$300.0M-$200.0M-$100.0M02019: -$105.2M-$105.2M20192020: -$129.6M-$129.6M2020+23%2021: -$183.3M-$183.3M2021+42%2022: -$201.3M-$201.3M2022+10%2023: -$274.0M-$274.0M2023+36%2024: -$104.0M-$104.0M2024−62%2025: -$121.2M-$121.2M2025+17%
Net income56784-$122.9M in 2025+29% since 2019
-$300.0M-$200.0M-$100.0M02019: -$95.2M-$95.2M20192020: -$121.0M-$121.0M2020+27%2021: -$178.3M-$178.3M2021+47%2022: -$192.3M-$192.3M2022+8%2023: -$257.8M-$257.8M2023+34%2024: -$97.9M-$97.9M2024−62%2025: -$122.9M-$122.9M2025+26%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Revenues$39.6M$57.8M
Research and development$112.7M$111.5M
General and administrative$34.9M$44.7M
Impairment of long-lived assets$13.2M$5.5M
Total operating expenses$160.8M$161.8M
Loss from operations-$121.2M-$104.0M
Interest income$1.3M$1.5M
Other (expense) income, net-$3.6M$4.3M
Loss before income taxes-$123.5M-$98.1M
Income tax benefit-$568.0K-$167.0K
Net loss-$122.9M-$97.9M
Basic net loss per share (in dollars per share)-$0.44-$0.49
Diluted net loss per share (in dollars per share)-$0.44-$0.49
Shares used in computing basic net loss per share (in shares)280.2M shares201.7M shares
Shares used in computing diluted net loss per share (in shares)280.2M shares201.7M shares

Compare SANGAMO THERAPEUTICS, INC with another company

Leadership

Who has led SANGAMO THERAPEUTICS, INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Edward O. Lanphier Ii.2006–2015
  2. Sandy Macrae2016–now

President

  1. Edward O. Lanphier Ii.2006–2015
  2. Sandy Macrae2016–now

Chief financial officer

  1. Henry Ward Wolff2007–2016
  2. Kathy Yi2017–2019
  3. Stephane Boissel2019
  4. Prathyusha Duraibabu2021–now
2010201520202025
Board members and other officers (43)

Former names

  • SANGAMO BIOSCIENCES INCMay 19, 2000 to Jan 6, 20172

Timeline

  1. Jun 6, 2016New chief executive Sandy Macrae becomes CEO13
  2. Jan 31, 2006New chief executive Edward O. Lanphier Ii. becomes CEO14

Filings

339 filings to the SEC since October 2021: 6 annual reports, 14 quarterly reports, 72 major events, 192 insider forms, 23 large holders, 32 other. The latest 20:

  1. Oct 7, 202625-NSE EDGAR
  2. Sep 21, 20268-K EDGAR
  3. Sep 8, 20268-K EDGAR
  4. Aug 28, 20268-K EDGAR
  5. Aug 17, 2026NT 10-Q EDGAR
  6. Aug 14, 2026SCHEDULE 13G/A EDGAR
  7. Aug 13, 20268-K EDGAR
  8. Aug 12, 20268-K EDGAR
  9. Jul 20, 20268-K EDGAR
  10. Jul 1, 20268-K EDGAR
  11. Jun 23, 20268-K/A EDGAR
  12. Jun 23, 20268-K EDGAR
  13. May 27, 20264 EDGAR
  14. May 27, 20264 EDGAR
  15. May 27, 20264 EDGAR
  16. May 27, 20264 EDGAR
  17. May 27, 20264 EDGAR
  18. May 15, 2026SCHEDULE 13G EDGAR
  19. May 14, 202610-Q EDGAR
  20. May 14, 20268-K EDGAR

The 339 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

16 open-market trades by officers, directors and large owners since October 2021: 2 buys and 14 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 22, 2026Davis Gregory DHead of Research & TechnologySale69,827$0.25$17.5KForm 4
Apr 21, 2026Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICERSale345,942$0.26$89.9KForm 4
Sep 26, 2023BIOGEN INC.10% ownerSale6,000,000$0.50$3.0MForm 4
Aug 30, 2022BIOGEN INC.10% ownerSale100,000$5.27$527.0KForm 4
Aug 29, 2022BIOGEN INC.10% ownerSale400,000$5.33$2.1MForm 4
Jun 3, 2022Markels JohnDirectorBuy6,784$3.69$25.0KForm 4
Jun 1, 2022PARKER H STEWARTDirectorBuy5,000$3.60$18.0KForm 4
Dec 28, 2021BIOGEN INC.10% ownerSale2,764$8.51$23.5KForm 4
Dec 27, 2021BIOGEN INC.10% ownerSale600$8.56$5.1KForm 4
Dec 23, 2021BIOGEN INC.10% ownerSale81,187$8.55$694.1KForm 4
Dec 9, 2021BIOGEN INC.10% ownerSale23,660$8.56$202.5KForm 4
Dec 8, 2021BIOGEN INC.10% ownerSale75,814$8.64$655.0KForm 4
Dec 7, 2021BIOGEN INC.10% ownerSale52,178$8.52$444.6KForm 4
Dec 2, 2021Biogen MA Inc.10% ownerSale1,874$8.51$15.9KForm 4
Dec 1, 2021Biogen MA Inc.10% ownerSale730$8.52$6.2KForm 4
Nov 26, 2021Biogen MA Inc.10% ownerSale28,884$8.60$248.4KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Nomura Asset Management International Inc.400,000$22.0K0.0%No change
Simplex Trading, LLC76,500$4.1K0.0%New
Axiom Investment Management LLC25,375$1.4K0.0%No change
Heritage Investment Group, Inc.10,000$5390.0%New
Flow Traders U.s. LLC21,532$10.0%+34
Barclays PLC1$00.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64